# Moonwalk Biosciences

> Biotech developing adipose-targeted RNAi medicines for obesity and cardiometabolic disease; raised $70 million Series B.

## Why it is interesting

Strong search demand and a differentiated obesity approach focused on adipose-selective RNAi rather than another GLP-1 program.

## Profile

- **Latest funding:** Series B — $70M (September 8, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $70M
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Alpha Wave, YK Bioventures, Eli Lilly and Company, ARCH Venture Partners, Khosla Ventures

## Key facts

- Sep 8, 2026: $70M Series B
- Lead program targets adipose tissue with RNAi for obesity

## Funding history

- Series B · $70M · September 8, 2026
  Source: https://moonwalk.bio/news/moonwalk-biosciences-announces-70-million-series-b-financing-to-advance-adipose-targeted-rnai-therapies-for-obesity-and-cardiometabolic-diseases/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/moonwalk-biosciences